Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07034690 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Study acronym: OPTIMA
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from Jun 23, 2026 to May 31, 2027 Completion pushed from Jun 30, 2027 to May 31, 2028v4 Show 1 more changeShow less
    • Completion pushed from Jun 30, 2027 to May 31, 2028
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 30, 2025 to Nov 26, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Nov 30, 2025 to Nov 26, 2025
    • Site details revised
  3. Start date: Jun 30, 2025 to Nov 30, 2025 Study sites: 0 to 1 · Secondary endpoints: details revised at 1 of 14 entriesv2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 1 of 14 entries
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Heart Disease
2,136 trials monitored
See 109 trials at risk
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.
Trial Details
NCT Number NCT07034690
Lead Sponsor Novartis Pharmaceuticals
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 326 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov